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ABSTRACT
Extracellular vesicles (EVs) are emerging as novel theranostic tools. Limitations related to clinical
uses are leading to a new research area on design and manufacture of artificial EVs. Several
strategies have been reported in order to produce artificial EVs, but there has not yet been a clear
criterion by which to differentiate these novel biomaterials. In this paper, we suggest for the first
time a systematic classification of the terms used to build up the artificial EV landscape, based on
the preparation method. This could be useful to guide the derivation to clinical trial routes and to
clarify the literature. According to our classification, we have reviewed the main strategies
reported to date for their preparation, including key points such as: cargo loading, surface
targeting strategies, purification steps, generation of membrane fragments for the construction
of biomimetic materials, preparation of synthetic membranes inspired in EV composition and
subsequent surface decoration.
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Extracellular vesicles in nanomedicine:
possibilities and limitations
Extracellular vesicles (EVs) represent an important por-
tion of the secretome. An overview of their functions in
physiological conditions of EVs was compiled by a
recent position paper from the International Society of
Extracellular Vesicles (ISEV) [1]. Some of the described
properties can be used for therapeutic uses, and their
testing has been transformed sometimes into several
registered clinical trials [2]. Exosomes are being applied
in antitumour immunotherapy [3], as therapeutic agents
against infectious diseases [4], unmodified exosomes for
immune-modulatory [5] and regenerative therapies [6],
and modified ones for targeted drug delivery [7], espe-
cially in gene therapy [8]. Although some of the
mechanisms behind their properties remain unde-
scribed, some general characteristics of EVs make
them advantageous over other therapeutic strategies.
Both the structure of the membrane and the forma-
tion route are the origin of the following advantageous
aspects: (1) high selective targetability and minimum
off-target effect, thanks to a set of molecules involved
in targeting, signalling and receptor-mediated uptake,
complete with all the co-receptors needed for the inter-
nalization process; (2) capacity of extravasation due to
a gel-state core derived from the presence of hydrated
macromolecules (proteins and nucleic acids) combined
with a minimum cytoskeleton that allows deformability
while keeping the whole integrity of the vesicle. (3) size
distribution; (4) great stability in the blood due to the
evasion of the innate immune system; (5) adaptative
responses that cause clearance from the blood, with the
corresponding decrease in bioavailability.
EVs can be used as a therapeutic agent by themselves or
as delivery systems. The great potential of EVs as drug-
delivery vehicles has been acknowledged in the literature
[7–12]. In most cases, the encapsulated drug acts in colla-
boration with elements naturally present in the EVs, creat-
ing a synergetic effect. In other cases, EVs serve only as
vehicles to reach a specific target population, sometimes
highly protected from conventional administration routes.
Nevertheless, limitations of EVs as therapeutic agents
have also been reported, including the absence of a good
definition from a pharmaceutical point of view [13], an
incomplete understanding of their role in the develop-
ment and spread of pathology, the absence of methods
for the isolation of homogeneous populations and sub-
populations of EVs, and cost-ineffective technology for
the availability of sufficient quantities for clinical trials
with constant characteristics. Moreover, it has been
acknowledged that there is little understanding on how
biological barriers are crossed by EVs, and a need for
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loading methods with scalable properties in clinical
translation has been identified [14].
Bio-engineered and mimetic EVs for
nanomedicine: classification of artificial EVs
EVs have been modified in the search for broader
therapeutic capability. Sometimes, this included the
incorporation of new elements for targeted puporses,
in vitro or in vivo traceability, or the material to be
delivered. In other cases, modification was aimed at the
enhancement of colloidal stability, or change in surface
charge to increase their uptake rate. These new
approaches have generated new terms such as bio-
engineered exosomes, artificial exosomes [15], exo-
some-mimetic nanovesicles [16], exosome-like nanove-
sicles [17,18] and exosome-based semi-synthetic
vesicles [19]. These expressions have been used with
different meanings in the literature, but to date, there
has not yet been a clear criterion for their classification.
One example is the term “exosome-like nanovesicles”.
In some works, this concept is used to name artificial
vesicles made from cells through different techniques
to mimic exosomes [17,18]. However, cell-derived vesi-
cles with morphological and biochemical characteris-
tics similar to exosomes were also named exosome-like
nanovesicles by other authors [19,20]. Other authors
working with non-animal research models used this
term to refer to vesicles with size and flotation density
values similar to those of exosomes. For example,
Regente et al. [21] described the presence of exo-
some-like vesicles in sunflower plant fluids, and
Prado et al. [22] showed evidence of vesicles quite
similar to exosomes during pollen germination.
In order to provide a systematic classification to
move around in this new emerging field, we suggest
the nomenclature given in Figure 1. This artificial EVs
landscape is based on the concept behind the term. In
this way, “artificial EVs” will be used as a general
concept to designate all vesicles, modified or manufac-
tured (from natural or synthetic sources), with the aim
to mimic EVs (mainly exosomes) for therapeutic uses.
Behind this term, two categories of artificial EVs can be
discerned: “semi-synthetic EVs” and “fully synthetic”
or “EVs mimetic vesicles”, corresponding to modified
natural EVs (pre- or post-isolation) and artificial struc-
tures, lab-made or generated from cultured cells.
The former generate semi-synthetic products, as
they start from a natural substrate, which can be sub-
sequently modified before or after their isolation. The
modification affects the structures of the outer surface
of the vesicles, the membrane or the cargo that travels
within, and could also include hydrophobic molecules
at the membrane.
The term fully synthetic, on the other hand, stresses
the artificiality of the product. We have recently briefly
commented their potential in therapeutics [23]. These
techniques can be classified on the basis of their man-
ufacturing route: those starting from larger substrates
(cells) that are reduced to units for the creation of
small size vesicles (top-down nanotechnology) or
those taking individual molecules (lipids, proteins,
etc.) that self-assemble in higher-order structures with
tunable composition (bottom-up nanotechnology).
Top-down products differ from natural EVs in terms
of micro-structure and biochemical composition, since
they are formed from cell fragments: the characteristic
membrane microdomains [24] (lipid rafts) and
Figure 1. Artificial EV landscape: explored routes to date for the preparation of artificial EVs for specific purposes. *EBSSNs [19].
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associated pools of surface markers (especially tetraspa-
nins) are absent, and the minimal cytoskeleton is not
present.
Impact of the artificial EV classification in the
design of new therapeutic agents based on EVs
The preparation route chosen is important for the final
purpose of artificial EVs, but it could be critical for the
clinical trials and subsequent commercialization. The
extensive manipulation of EVs during the bio-engi-
neering methods is the reason for their classification
as advanced therapy medicinal products (ATMPs) [2],
with a particular regulatory framewok. Following the
same criteria, fully artificial EVs produced from cul-
tured cells (top-down) should also be incorporated into
this category.
On the other hand, bottom-up artificial mimetic
EVs are more difficult to assign to one or another
category. To date, a set of proteins have been fixed
on lipidic vesicles with an undefined purpose. While
there is some evidence that the EV membrane is
important for the uptake process [1], the role of the
artificial membranes is not yet clear. Comparative stu-
dies of the effects over target cell lines with conven-
tional liposomes and exosome-mimetic nanovesicles
would be very useful to clarify this. The work in this
field is reviewed in the section “Bottom-up methodol-
ogies: artificial membranes decorated with functional
proteins to mimic EVs functions.”
A critical evaluation of the fully synthetic EVs con-
cept would imply providing an answer to questions
such as: “What we are trying to mimic from EVs?”;
“Is the biochemical composition, the morphology or
the whole entity?”; “Is it worth mimicking a specific
function?” This is still a challenge in the field, since
some of these questions are being answered at the same
time for natural EVs. The best approach would involve
an extensive biochemical characterization of natural
EVs and a detailed description of their functions.
Regarding functionality, other populations and not
only the target cell lines should be assayed. This
could provide information about possible side effects.
In the same way, multiple parameters should be regis-
tered as output factors, not just the process targetted by
the EV-based treatment. Proteins, nucleic acids and
lipid composition from specific types of exosomes are
registered in specialized databases such as ExoCarta
[25], EVpedia [26] and Vesiclepedia [27]. But this is
not enough: a database with assays performed with EVs
reporting treated cell lines, EV type as therapeutical
agents, type of assay (in vitro or in vivo) and experi-
mental conditions could be of great interest to the
scientific community. The combination of both sources
of information would be the perfect scenario for the
design of future artificial EV-based therapies.
In any case, both types of artificial EVs should meet
product specifications related to “purity, identity,
quantity, potency and sterility” in concordance with
the pharmaceutical market regulations [28]. Once
more, there are several important differences in the
definition of these parameters depending on the semi-
or fully synthetic character of EVs. These key points
will be considered and discussed in the following
sections.
Semi-synthetic exosomes: biotechnological
modification of naturally released exosomes
The simplest idea to manufacture EVs would be to use
the natural mechanisms for the formation of vesicles,
that is, the cellular machinery itself. It is known that
the composition of the EVs at all levels responds to a
high degree of control at very selective cellular
mechanisms [29]. Therefore, the composition of the
EVs could be controlled by intentional alteration of
the cellular environment.
This method would lead to the creation of EVs with
a composition profile adapted to a specific purpose.
The technological methods used for bioengineering
EVs are explained in the following sections. Two key
aspects are the selection of producer cells (and their in
vitro harvesting conditions) and the EV isolation/
enrichment procedures. Both choices will condition
subsequent uses.
Selection of EV cellular origin
Cell lines could potentially release EVs vesicles, but
there are great differences in release rate and biochem-
ical composition and their susceptibility to modifica-
tions [30]. It is also accepted that before translation to
clinical use of EVs, limitations regarding biocompat-
ibility, economic viability, harvesting methods and
immunotolerance must be overcome. A summary of
cell lines used for the production of EVs for clinical
purposes, especially drug delivery, can be found in the
literature [31]. Dendritic cells and cancer cell lines,
such as melanoma, are the most commonly used lines
for EV production.
Mesenchymal stem cells (MSCs) are one of the most
promising sources of EVs, especially exosomes [32].
Yeo et al. [33]. defended their use for mass production
of exosomes with future therapeutic purposes based on
some important facts related to their advantages over
other cell lines. Mainly, MSCs are easy to obtain from
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all human tissues (even those considered as medical
waste), and they have a high ex vivo expansion capacity
compatible with immortalization without compromis-
ing their therapeutic efficacy. These two facts are essen-
tial to establish a scalable and long-term source of well-
characterized EVs, particularly exosomes [14,28]. In
addition, their immunomodulatory effect gives them
and their derived EVs important features in autologous
and allogenic therapeutic applications.
Dendritic cells (DCs) have important roles in immu-
nity (both innate and adaptative). Some authors have
paid attention to this cell line in order to enhance the
production of clinical grade DC-derived exosomes for
immunotherapy [33]. Properties of DCs have even
been enhanced with different nanoparticles [34].
Exosomes from DCs modified to express indoleamine
2,3-dioxygenase (IDO), a tryptophan-degrading
enzyme that is important for immune regulation and
tolerance maintenance, have been used in the treat-
ment of rheumatoid arthritis [35]. In another study,
DC-derived exosomes modified to express FasL on the
surface (ligand involved in apoptosis induction) were
tested as inflammatory and autoimmune therapy [36].
Other recent works are related to the role of tumour-
released exosomes to load antigens into DCs for the
therapy of malignant mesothelioma [37].
To overcome the problem of low release rate, some
authors lowered the micro-environmental pH, mimick-
ing the natural cancer mechanism [38]. By culturing
HEK293 cell lines at different pHs, these authors found
that low pH values were best to isolate high amounts of
exosomes. In spite of the impact of these results, it
would be necessary to test similar effects in non-can-
cerous cell lines and to determine how the change in
the harvesting conditions affects EV composition
(membrane components and cargo).
Not only human cells have been explored as a source
of EVs: exosomes isolated from bovine milk and loaded
with different drugs were a promising strategy for mass
production of therapeutic EVs [39]. They can be easily
isolated by differential centrifugation. The biocompat-
ibility of milk-derived exosomes was checked by clin-
ical biochemical analysis in an animal model by oral
gavage during 6 h (short-term toxicity) and 15 days
(medium-term toxicity).
In recent years, some attention has been drawn to
non-animal (especially plant) EVs and their potential
use in therapy [40]. In particular, fruit-derived exo-
somes (lemon [41] and grapes [42]) have been isolated,
characterized and tested as beneficial products. Perhaps
this new source of EVs could be used in the near future
for the development of EBSSNs following modifica-
tions to express the desired targeting molecules against
specific cell lines. Evidence about immunotolerance
should also be provided in order to avoid any inter-
ference in the results.
In any case, studies involving the encapsulation of
the same drug into different cell lines-derived EVs
would be desirable in order to clarify whether the
beneficial effect is due to the drug or the combination
of drug/type of carrier.
Obtaining a good substrate for modification:
isolation procedures
Since the final destination of artificial EVs would be the
administration for therapeutic purposes, the highest
level of standards would be required in order to pre-
serve patient safety [27,43]. A key point in artificial
EVs development is the enrichment from different
biological samples, from cell-culture supernatants to
several body fluids. There are different reviews [43–
45] and technique-comparative papers [46–49] about
isolation procedures. They involve ultracentrifugation,
filtration, immunoaffinity isolation, polymeric precipi-
tation and microfluidics techniques, with different
degrees of purity for the final product [50]. In this
review, we have focussed on scalability, reproducibility
and synthetic EV potential damage or physical
modification.
Since the efficient function of EVs depends on their
size distribution, aggregation and size changes after
isolation are important. Lane et al. [47] studied these
parameters in four isolation methods: two aggregation
kits, a density-based method and ultracentrifugation.
These authors found that some methods kept a con-
stant vesicle size, but large differences were observed
regarding yield of isolation (the two sedimentation
methods gave recovery values two orders of magnitude
higher than the other methods). Another reported
obstacle is the co-purification of material with similar
physical characteristics to EVs [42,51,52].
Scalability is also important, since the batch size is
correlated with the homogeneity of the final product;
sometimes small batches are more prone to being sus-
ceptible to bias during the process, but on other occa-
sions, higher batches yield more heterogeneous
populations due to microenvironments during
procedures.
The scale-up step with ultracentrifugation (UC) is
limited by the number of rotor positions and the max-
imum sample volume. On the other hand, methods
such as size exclusion chromatography (SEC) are easy
to scale up by using large columns, but with the asso-
ciated longer separation time. Pressure application to
reduce processing time can disturb EVs [43]. Other
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methods, such as immunoaffinity isolations, are only
used for small amounts of original sample because of
the high price of the reagents required. Finally, micro-
fluidic methods [45,53] are promising, with the possi-
bility of being coupled to online analysis [54].
Reproducibility is crucial when the product is going
to be used in the clinical field. Comparative results of
UC are difficult to obtain due to the high number of
models available in the market, and this could affect
the quality of the isolated product [43]. The use of a
fixed instrument would keep low variability between
batches [47].
Welton et al. [55] reported that ready-to-use SEC
columns could overcome some problems related to
homemade poured columns [52], thereby avoiding var-
iations from column to column, and facilitating robust
protocols to be used routinely. The main problem asso-
ciated with this method is dilution of EVs in the final
sample and the subsequent need for concentration using
precipitating agents or UC. This increases retention
time and the possibilities of co-precipitation of other
molecules with the same size and physical properties.
Considerable effort has been made in the field of EV
isolation methods, which are still limiting the expan-
sion of this field. There is not yet a perfect and uni-
versal method, and it is also accepted that selection of
the isolation method could impact downstream
steps [56].
Strategies for biochemical modification
Pre-isolation modification using own cellular
machinery
The advantages and disadvantages of the methods
applied to incorporate proteins of nucleic acids are
shown in Tables 2 and 3. Based on the study of exosome
biogenesis-related mechanisms, several methods have
been developed [50,57–62]. The following criteria have
been identified for their classification (see Table 1):
(I) location of exosomal functional entities, such as
transmembrane proteins and the use of their
natural tropism to co-localized the exogenous
element;
(II) strategies using molecular mechanisms for the
introduction of exogenous molecules into EVs
for cytosolic delivery;
(III) increasing the amount of molecules into the cel-
lular plasma to be encapsulated by passive
mechanism during MVB formation.
Class I methods (Table 2) involve the design of chi-
meric constructions of proteins by genetic engineering.
In this case, the fusion between the gene of a protein to
be incorporated and the gene of an exosomal-localized
protein can be used for the expression of the former on
the outer surface of exosomes. This has been referred
to in the literature as Exosome Display technology [63],
and it enables the manipulation of the protein content
of exosomes and the subsequent tailoring of activities.
The potential of the method was successfully demon-
strated by the production of specific antibodies against
human leukocyte antigen (HLA), a low immunogenic
antigen [64].
Lactadherin C1C2 domain was also used for simi-
lar purposes by Zeelemberg et al. [65] and Hartman
et al. [66] to induce expression of chicken egg oval-
bumin (OVA) peptide and the human epidermal
growth factor receptor 2 antigen (HER2), respec-
tively. Álvarez-Erviti et al. [67] described a method
of inducing surface expression of the central nervous
system-specific rabies viral glycoprotein (RVG) pep-
tide on exosomes isolated from immature dendritic
cells derived from mice. Complementarily, these
brain-targeted exosomes were loaded with siRNA
for the first time by electroporation. The delivery of
Table 1. Classification of techniques for the production of
artificial EVs, mainly exosomes, according to type of final pro-
duct (semi- or fully synthetic) and the principle of the obten-
tion mechanism.
Semi-synthetic exosome production: modification of vesicles naturally
produced by cells
Pre-isolation modification
Class I Co-localization of cargo and exosomal carrier
moiety thanks to the natural tropism of
the second
Class II Use of sequences (i.e. nucleic acid-based
sequences) for the exosomal biogenesis
pathway signalling
Class III Take advantage of passive loading via
increments of their presence, by genetic
overexpression or active loading of
producer cells
Post-isolation modification
Class IV or passive
methods
Methods that use passive adsorption of
molecules into external surface of EVs,
owing to their hydrophobicity nature
Class V or active methods V.a (Physical methods), based on the creation
of transitional alteration in the integrity of
EVs that allows cargo to enter the vesicles
by concentration gradient or by passive
incorporation during subsequent restoring
of initial status post-stimuli
V.b (Chemical methods), based on induced
chemical reactions between EVs and cargo
with or without previous introduction of
functionalization agents into vesicles
Creation of artificial mimetic structures of the natural exosomes
Type I or top-down bio-
nanotechnology
Starting from larger substrates (cells) that are
reduced to units for the creation of
vesicles with reduced size
Type II or bottom-up bio-
nanotechnology
Starting with individual molecules (lipids,
proteins, etc.) that are assembled in a
controlled way for generating complex
structures of higher order
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GAPDH-siRNA specifically to neurons, microglia
and oligodendrocytes in the brain resulted in a spe-
cific gene knockdown. This was considered the first
example of EV-based genetic therapy. One of the
most important facts of this work was the successful
treatment of a highly protected tissue, the brain, in
spite of the existence of brain–blood-barrier
selectivity.
Tian et al. [68] used lysosome-associated membrane
glycoprotein 2b to target electroporated doxorubicin-
loaded exosomes (20% of loading efficacy) produced in
dendritic cells. Ohno et al. [69] used platelet-derived
growth factor receptor transmembrane domain to anchor
GE11 peptide, a ligand of the epidermal growth factor
receptor (EGFR). This construction was transfected to
Human Embryonic Kidney cell line 293 (HEK293) using
pDisplay vector and FuGENE HD transfection reagent.
As amodel cargo, siRNA let-7was selected for its ability to
alter cell-cycle progression and reduce cell division in
cancer cells. This siRNAwas introduced intoEVproducer
cells by the lipofection method. Modified exosomes (15–
21% of total released exosomes) were isolated by centri-
fugation and intravenously injected into an animal model
with induced breast cancer. GE11 peptide as the targeting
moiety was selected by the elevated expression of his
receptor (EGFR) in tumours of epithelial origin.
More recently, Stickney et al. [62] developed another
genetic engineering method for surface expression of pro-
teins in human cells, called surface display technology. In
this case, tetraspanin CD63 was used as a scaffold for the
presentation in both extravesicular and intravesicular
orientations.
Class II methods include a heterogeneous group of
strategies that have in common the use of specific
molecular interactions between two elements and can
be used to transport the complex into the exosomes.
One example of this strategy is the interaction between
specific sequences in RNAmolecules and proteins that are
present in the route of exosomes formation [16]. Highly
observed sequence motifs into RNA types studied in EVs,
called EXOmotifs, were found in mRNA [70] and miRNA
[71]. Exosomes for Protein Loading via Optically
Reversible protein–protein interactions (EXPLORs) and
Targeted and Molecular EV Loading (TAMEL) are tech-
nologies based on the molecular interaction between cer-
tain types of proteins or between RNA special structures
and specific proteins. Proteins of interest can also be loaded
into the inner compartment of exosomes for their direct
Table 2. Pre-isolation methods for cargo incorporation into EVs.
Cargo incorporation previous to the release of exosomes
Method
EV
modified
component
Category of
modification
(according
with Table 1) Advantages Disadvantages Molecules incorporated
Genetic fusion of
cargo gene
with an
exosomal
protein gene
Surface Class I Efficient exposure of targeting
moiety on the surface of EVs
By selecting the EVs protein to
be fusioned with, different
expression rate can be
achieved
Only successfully explored with
exosomal membrane proteins
Peptides, small proteins
such as GE11 peptide
[69], HLA [63], OVA [65],
HER2 [66], and RVG [67]
Exosome surface
display
technology
Surface Class I Suitable to induce expression of
protein in both, extravesicular
and intravesicular sides at the
same time
Not tested with high-molecular-
weight proteins
Fluorescent proteins [62]
such as GFP and RFP
RNA zipcodes Cargo Class II Alternative to electroporation of
miRNA
Applicable only to mRNA and miRNA
Influence of mRNA size not tested
mRNA [70] and miRNA [71]
modified with zipcodes
EXPLORE
platform
Cargo Class II Excellent platform to load
proteins to be delivered to the
cytosol of the target cell
Expected better results than
commercial solutions available
Limited loading capacity due to the
presence of fluorescence reporter
proteins in future work, this
protein can be omitted
mCherry, Bax, SrIκB and Cre
recombinase proteins [61]
TAMEL platform Cargo Class II By selection of one component
of the platform, the EV-
enriched protein loading
efficiency can be controlled
Highly cost-effective method
Required highly experimented
personal
EE values depending on RNA
molecule size
RNA [59] with variable
length
Overexpression of
RNA cargo into
producing cells
Cargo Class III Used in all types of exosomes
Applicable to all types of RNA
Nonspecific loading mechanism
Low efficiency, especially for mRNA
RNA and proteins by
expression of RNA into
cell producer cytosol
Fusion with
liposomes
Surface
and/or
cargo
Class III High efficiency
Both hydrophilic and
hydrophobic compounds can
be loaded
Cellular uptake rate can be decreased
Better efficiencies for hydrophobic
molecules
Hydrophobic and
hydrophilic compounds,
such as DiI and calcein
respectively [72]
Photosensitizer drugs, such
as ZnPc [72]
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delivery to the cytosol of the target cell as an alternative for
therapeutic target locations. EXPLORs [61] has recently
presented for that purpose. The system integrates two ele-
ments: one is produced by the genetic fusion of the photo-
receptor cryptochrome 2 (CRY2) to the protein to be
loaded, and the other is made by the fusion of a truncated
version of the CRY-interacting basic-helix-loop-helix 1
(CIBN) to tetraspanin CD9. Both elements can be transi-
torily attached by exposure to blue light, which induces the
interaction between CRY and CIBN, and the interaction
can be stopped once the blue light is not present.
TAMEL is another genetic engineering tool that
has recently been published [59] for the active cargo
of RNA. This platform is a fusion between an engi-
neered EV-loading protein and the RNA to be loaded.
Engineered EV-loading protein is also a fused product
between an EV-enriched protein and an RNA-binding
domain. This construction is transfected into EV pro-
ducer cells to make his function. Different loading
degrees can be obtained by selecting the EV-enriched
protein. This is related to the natural expression of
different proteins into EVs.
Class III methods includes the simplest method:
passive loading into vesicles through their biogen-
esis. There can be two different approximations to
this objective. First, the overexpression of RNA
cargo in the producer cells. The major disadvantage
of this method is the lack of selectivity in the load-
ing process, since it is gradient-driven (the higher
the concentration in the cytoplasm, the higher its
possibility of being trapped into exosomes during
invagination of MVB formation). On the other
Table 3. Post-isolation methods for cargo incorporation into EVs.
Cargo incorporation after the release of exosomes
Method
EVs Modified
component
Category of
modification
(according
with Table 1) Advantages Disadvantages Molecules incorporated
Co-incubation
with
exosomes
Cargo Class IV The simplest method
Inexpensive
Compatible with the addition
of a small amount of organic
solvent for the enhancement
of hydrophobic drug
dissolution
More suitable for
hydrophobic molecules
Low- and medium-molecular-weight
hydrophobic molecules such as
curcumin [74], placlitaxel [95],
cucurbitacin I [75], celastrol [76]
and different porphyrins [58]
Enzymes, such as catalase [80]
Electroporation Cargo Class Va Used in all types of exosomes
Able to incorporate large
compounds, such as 5 nm
NPs
Applicable only for
hydrophilic compounds
RNA type-dependence
effectiveness
Slight differences in EE
depending on the
cellular origin (cell line)
of the exosomes
Induce aggregation of
siRNA, with valuable
reduction in EE.
Exosome aggregation trend
during electroporation
process
RNA, especially siRNA [67]
Different drugs such as placlitaxel
[60], porphyrins [58]
SPIONs [79]
Extrusion Cargo Class Va Simple method Induces changes in EVs
which reduce delivery
efficiency
Small molecules such as Porphyrins
with different hydrophobicity [58]
Enzymes, such as catalase [80]
Saponin-
assisted
loading
Cargo Class Va Similar loading efficiency to
electroporation, but without
the associated problems
Saponin can enhance in some
cases the efficiency of co-
incubation
Low efficiency for some
large molecules, but
better than simple
incubation
Hypotonic
dialysis
Cargo Class Va Not tested with large
molecules
Sonication Cargo Class Va Enhance simple incubation
through decreasing bilayer
rigidity
Not tested with hydrophilic
molecules
Not tested with different EV
populations
Small molecules such as placlitaxel
[95] or Doxorubicin
Enzymes, such as Catalase [80]
Click chemistry Surface Class Vb Keep constant morphology or
functionality of EV properties
Applicable to any molecule
previously modified
A two-step procedure with
subsequent purification
steps to remove
unbound molecules and
activate agents
Fluorescent dyes such as azide-Flour
545 [81]
Potentiality to any type of molecule
susceptible to being modified by
azide groups
Fusion with
liposomes
Surface and/or
membrane
Lipids with different chemical nature
[85] (zwitterionic, cationic,
anionic, PEGliated, etc.)
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hand, the great advantage of the method is that by
translation of mRNA into receptor cell cytoplasm,
codified proteins can also be passively loaded
into EVs.
The second approximation explores the active load-
ing of the producer cells, i.e. by nanocarriers such as
fusogenic liposomes. This strategy is based on phy-
sico-chemical properties that govern the type of
mechanism (the fusiogenic properties of the two ele-
ments that take place in the method, cells and lipo-
somes). Second, they modify the whole cell and not
only the exosomes.
As an alternative method for the incorporation of
exogenous molecules (specially designed for hydro-
phobic compound) into EVs, Lee et al. [72] pre-
sented the use of membrane fusogenic liposomes
(MFLs). By the treatment of cells with MFLs loaded
with a hydrophobic compound (DiI) and a hydro-
philic molecule (calcein), these authors obtained
EVs modified with both molecules. Only slight dif-
ferences in the efficiency of incorporation into EVs
were found, since a hydrophobic compound would
remain in the plasma membrane after liposome
fusion and in the subsequent formation of EVs
membrane through their routes of biogenesis. In
contrast, a hydrophilic molecule would be released
into the cytosol. Intercellular transport of both
molecules mediated by EVs was successfully
observed in vitro in a multicellular tumour spheroid
model.
A similar method was used to modify the composi-
tion of EVs, with a special focus on the modification of
the properties of the EV membrane [57]. Dyes, fluor-
escent lipids with different lengths and saturation grade
of acyl chains, and chemotherapeutics were loaded into
cells by means of EVs.
These authors also carried out a membrane sur-
face modification, with the possibility of conjuga-
tion with molecules for targeting purposes. They
first prepared MFLs containing azide-modified
lipids which were fused with cells. By simple incu-
bation with dibenzocyclooctyne (DBCO)-modified
peptides, a covalent bond was created due to the
fast and selective reaction between DBCO and the
azide group [73]. This strategy will allow new pos-
sibilities of surface ligand decoration on EVs for
targeting purposes (such as peptides, aptens or anti-
bodies) or for the introduction of molecules with
therapeutic properties via interaction with selective
receptors. By the combination of a different head-
group modified lipids, several different ligands
could be incorporated into EV outer membranes,
including receptors and co-receptors.
Physical and chemical post-isolation modifications
These are the methods that require an external force
(chemical or physical) to incorporate new molecules on
previously isolated exosomes (Table 3).
Passive methods. Incubation of EVs and cargo. The
simplest way to incorporate any cargo into cell culture
or body fluid isolated EVs is the co-incubation of both
elements. This strategy was explored by Sun et al. [74],
who found that curcumin exosome-loaded exhibited a
better stability and higher bioavailability in serum in an
animal model. For these therapeutic-modified exo-
somes, an improvement in in vivo anti-inflammatory
and septic shock was observed.
In another study [75], two anti-inflammatory com-
pounds were loaded into exosomes and microparticles,
and they were administrated intranasally, opening up
new therapeutic possibilities. The effects of solvents
and drug release kinetics from loaded exosomes by
dialysis have been studied [39,76].
Active methods. Physical methods: electroporation and
other temporary membrane disruptive methods. The
most commonly used method for cargo incorporation
into EVs after their release is electroporation [77]. This
technique involves the temporary permeabilization of
membranes through the creation of pores due to the
application of high-voltage electricity. Some authors
have pointed out that this method is not suitable for
siRNA cargo into EVs due to technical problems, and
an overestimated encapsulation into EVs could be
observed. It has been reported that electroporation
induces siRNA aggregation and co-pelletization with
EVs during purification by ultracentrifugation, without
any dependence on electroporation buffer composition
[78]. They also postulated that slight differences could
be found between different EVs regarding their cellular
origin (e.g. primary cells).
Another relevant problem concerning electropora-
tion is exosome aggregation and subsequent decrease
in functionality. To avoid these problems, Hood et al.
[79] electroporated exosomes from mouse B16-F10
melanoma cells by incorporating 5 nm superparamag-
netic iron oxide nanoparticles (SPIONs) as model exo-
genous cargo. Other authors compared the loading
efficiency of different porphyrins with different hydro-
phobicities into EVs with various origins by passive
loading (co-incubation), and by active loading, such
as electroporation, extrusion, saponin-assisted drug
loading and hypotonic dialysis [58]. The best results
were obtained for hydrophobic compounds and for
electroporation. Interestingly, zeta potential (ζ) related
to the chemical composition of EV membranes seems
to play a role in loading efficiency, since higher ζ values
led to higher EE. The chemical properties of cargo are
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also relevant, since their charge will condition the final
outcome. Electroporation did not induce drug
precipitation.
In contrast, extrusion over polycarbonate mem-
branes altered the morphology of vesicles and, sub-
sequently, their delivery efficacy. Other authors used
the sonication of EVs in the presence of drug solu-
tions [60].The loading efficacy was found to follow
the order: incubation at RT < electroporation ≪
mild sonication. A similar trend was observed for
size changes after the loading procedure. On the
other hand, surface charge and protein profile were
similar after loading, evidencing no alteration in
exosome stability. These authors explained the
results concerning sonication as a decrease in bilayer
rigidity after sonication, which allowed a better
incorporation of the hydrophobic drug. Therefore,
mild sonication should be considered as an enhance-
ment of co-incubation. Additionally, loaded exo-
somes were stable over large periods of time at
different temperatures.
A similar comparative study was carried out with
the enzyme catalase [80]. For the preparation of
exosomes modified with this oxidative stress-protect-
ing agent used for the treatment of Parkinson’s dis-
ease, these authors selected four methods: incubation
at RT in the presence/absence of saponin, freeze/
thaw, sonication and extrusion. Sonication yielded
the higher EE (26.1%) and the more stable product.
In contrast, this method also produced the higher
increment in size, from 105 nm naïve exosomes to
183.7 nm in catalase-loaded exosomes. Associated
with size increment, AFM observation also revealed
a change in morphology, with a final non-spherical
shape.
Despite these promising results regarding the encap-
sulation of different molecules into exosomes, standar-
dization in systematic conditions followed by the study
of several cell lines is still necessary to strongly support
the use of these methods as routine practice in the
clinical field.
Chemical methods: click chemistry mediated functionaliza-
tion and other targeted drug-delivery strategies. The che-
mical copper-catalysed reaction between an alkyne and an
azide that forms a triazole linkage (click chemistry) has been
used for the surface functionalization of exosomes [81].
These were first chemically modified by the incorporation
of alkyne groups into amine groups from proteins by
carbodiimide chemistry [82]. These authors conjugated
azide-Fluor 545 (a fluorescent compound) to activated
EVs. Since no differences in morphological and functional
properties were found, it was concluded that modification
by click chemistry does not alter exosome characteristics
and allows the incorporation of exogenousmolecules to the
surface of EVs.
Finally, there is another type of cargo modification
that has been applied into artificial vesicular systems
(liposomes) with potential applicability to EVs. This
method is based on the ability of some peptides to be
incorporated into lipidic membranes causing disrup-
tion [83,84]. By fusion of the peptide D1-7 to an adhe-
sion molecule expressed in cells, targeted lipidic
carriers with therapeutic cargo were produced and
successfully tested in vitro and in vivo. Another inter-
esting application of this strategy is its ability to insert
peptidic cargo into live cell membranes, giving possi-
bilities of imaging live cells and modifying cell surfaces.
This last property could be explored for the modifica-
tion of plasma membrane in EV producer cells.
The modification of EV membranes results in
changes in surface charge, fusiogenic properties,
immunogenicity decrease and colloidal stability [85].
Engineered hybrid exosomes were prepared by mem-
brane fusion with liposomes formulated with different
types of lipids (i.e. zwitterionic, anionic, cationic and
PEGlilated). Fusion properties with cell-culture-derived
exosomes were studied according to the chemical nat-
ure of liposome lipids [86]. It was found that zwitter-
ioninc and anionic lipids did not alter the uptake rate,
while the introduction of cationic lipid greatly
decreased the phenomena, and PEGilated lipid
increased it by twofold. Therefore, it can be concluded
that functional properties could be tuned by modifying
the membrane composition.
Top-down and bottom-up methods for the
development of full synthetic EVs
Production of artificial EVs by generation of
plasma membrane fragments: a top-down-inspired
methodology
Different approaches based on top-down nanotechnol-
ogy have been developed for the production of EVs
mimetic nanovesicles using cells as precursors of plasma
membrane fragments. Those strategies rely on the prin-
ciple of self-assembly of lipids and lipid membranes into
spherical structures and the encapsulation of surround-
ing material into the aqueous cavity of generated nano-
vesicles. Current methods include extrusion over
membrane filters [16,17,87], hydrophilic microchannels
[88] or cell slicing by SixNy blades [18] (see Table 4).
Extrusion over polycarbonate membrane filters
Jang et al. [16] used a serial extrusion through poly-
carbonate membrane filters with decreasing pore sizes
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(10 μm, 5 μm and 1 μm) in a mini-extruder, similar to
those commonly used for the preparation of liposomes.
Human monocytes were chosen as precursors for
membrane fragments. The yield production of NVs
was 100-fold in comparison with the production of
exosomes by using the same number of cells.
Morphological studies of these NVs by crio-TEM and
NTA showed many similarities with the exosomes,
round shape and a peak diameter around 130 nm.
Even the exosomal protein marker profile (CD63,
Tsg101, moesin and beta-actin) checked by Western
blot was identical for the NVs and exosomes. The
chemotherapeutic drugs, doxorubicin, 5-FU, gemcita-
bine and carboplatin were added to the buffer where
cells were resuspended. The encapsulation efficiency in
the final purified NVs was found to be dependent on
the initial amount of added drug.
Looking for a scaled-up process using extrusion as
the generation procedure of NVs, Jo et al. [87] devel-
oped a device that uses centrifugal force to extrude cells
over polycarbonate filters (10 μm and 5 μm pore sizes).
The device has a central piece where filters are located
and connected to two syringes where the sample is
dispensed by the centrifugal force. Uniformly sized
100 nm NVs with a yield 250-fold higher than that of
exosomes from the same number of cells was achieved.
Analysis of the filters by TEM showed that many cells
remained trapped in the structure.
The same device previously cited was employed by
Jeon et al. [17] to produce exosome-mimetic NVs from
murine embryonic stem cells for the treatment of mice
isolated skin fibroblasts. These authors wanted to
explore the potential of mimetic exosomes to induce
proliferation and recovery after injury in an in vitro
model. Genomic and proteical profiles similar to origi-
nal cells were assessed by PCR and Western blotting of
specific markers, and it was confirmed that successful
delivery of genetic material by NVs was reached.
Pressurization, extrusion and slicing over hydrophilic
parallel microchannels in a microfluidic device
Jo et al. [87] produced exosome-mimetic nanovesicles
by extruding cells over hydrophilic microchannels,
with the aim of delivering endogenous RNA across
the plasma membrane with high efficiency and low
toxicity. These authors developed a microfluidic device
made of PDMS by soft lithography. This device had an
array of 37 parallel microchannels, with a common
inlet and outlet connection for the pumping with a
syringe pump and the collection of NVs, respectively.
The higher amount of nanovesicles generated by extru-
sion over hydrophilic channels with a similar size to
exosomes was obtained with a length of 200 μm and a
width of 5 μm. These results showed that an appro-
priate total shear force induced by the channel has to
be reached in order to produce NVs with acceptable
results. This force is responsible for NV generation due
to elongation of the plasma membrane on the micro-
channel surface. When the elongated membrane
reaches a certain value, it breaks into small portions
Table 4. Summary of the published work about the generation of mimetic EVs nanovesicles by top-down bio-nanotechnology (cell
source and type of cargo are encapsulated, and main characteristics are given).
Generation technique Precursor cell type
Type of material
encapsulated Nanovesicles characteristics Reference
Manual extrusion over
polycarbonate membrane
filters
Monocytes and
macrophages
Exogenous,
chemotherapeutic
drugs
Mean size and distribution similar to that of exosomes
Exosomal protein profile similar to that of natural exosomes
EE of chemotherapeutics dependent on the original amount
used during extrusion
High rate of drug release
100 times more that of nanovesicles than exosomes from the
same number of cells
Results reproducible with different cell types
[16]
Pressurization and extrusion
over hydrophilic parallel
microchannels in a
microfluidic device
Murine embryonic
stem cells
Endogenous, proteins
and RNA
Average size in the exosome range
Similar intracellular and membrane protein and total RNA profile
to the original cells and exosomes
Same ability to deliver RNA content as exosomes
[88]
Centrifugal force and
extrusion over a filter with
micro-size pores into a
polycarbonate holder
structure
Murine embryonic
stem cells
Endogenous, proteins
and RNA
NVs size and morphology similar to exosomes
Cargo of RNA, intracellular proteins and plasma membrane
proteins similar in types to exosomes
Small RNA profile differs in quantity, especially in miRNA with
respect to exosomes
Intravesicle contain twice the concentration of natural exosomes
250 times more vesicles than naturally secreted exosomes
[87]
Slicing living cell membrane
with silicon nitride blades
in a microfluidic device
Murine embryonic
stem cells
Exogenous,
polystyrene latex
beads
Generated NVs in the size range of exosomes
Nanovesicle production 100 times more productive than natural
exosome
30% of EE for 22 nm nanoparticles as model of exogenous
material encapsulation
NVs can deliver exogenous encapsulated material
[18]
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that directly form nanovesicles, thanks to the self-
assembly property of lipids in aqueous media.
With the appropriate channel morphology, these
authors produced 100 nm nanovesicles similar in com-
position (proteinical and nucleic acid profile) to natu-
rally produced exosomes. The analysis of these NVs
[88] revealed that the formation of exosome-like NVs
through hydrophilic channels produced a delivery sys-
tem of endogenous material with identical results to
those with exosomes.
More recently, Yoon et al. [18] reported the produc-
tion of exosome-mimetic nanovesicles by the slicing of
cells through SixNy blades aligned to the flow direction
over hydrophilic microchannels. These authors com-
bined the induced shear stress formation on NVs with
the fragmentation of plasma membrane by the blades
to obtain fragments for the generation of exosome-like
nanovesicles and the co-encapsulation of exogenous
material (polystyrene latex beads as a model sub-
stance). It was found that NV diameter increased as
the width channel increased. This is because channel
morphology is proportional to the Reynolds number
(Re). In this particular case, Re is proportional to the
hydraulic diameter and, therefore, to the inertial force,
which directly increases with the channel width. In
other words, NVs travelling through wide channels
have a higher inertial force when they reach the blades,
generating larger sliced fragments that produce larger
NVs. These have a similar composition to that of
parental cells and naturally released exosomes by
those cell lines.
One of the most interesting works in the literature
[18] describes the encapsulation of 22 nm fluorescent
polystyrene latex beads as an exogenous simulated
material, adding these nanoparticles to the media
where cells were diluted before slicing. With a final
corrected EE of 30%, these NVs containing exogenous
material were given to fibroblasts in an in vitro experi-
ment. After a period of time, red dots corresponding to
fluorescent beads were detected in the cytoplasm of
fibroblast by confocal microscopy. The delivery effi-
ciency of encapsulated beads into exosome-like NVs
was higher than that of bead-aggregated NVs, revealing
that exogenous material delivery with these NVs was
possible, but the efficiency was still lower than that
achieved with parental cell-component generated NVs.
Bottom-up methodologies: artificial membranes
decorated with functional proteins to mimic EV
functions
The third option for obtaining artificial EVs is their
construction in a fully synthetic way by assembling
individual molecules (lipids, proteins and cargo) into
complex structures, such as a bilayer structure resem-
bling EV membranes functionalized with proteins for
mimicking EV functions. This could be achieved by
assuming that not all components in natural exosomes
are essential for specific and efficient delivery [13],
including the transport of a message through direct
contact with target cell receptors. Another assumption
that encourages researchers to explore this route is
that, from a structural and biochemical point of view,
exosomes are liposomes with attached proteins.
Therefore, this type of vesicular system could be an
ideal substrate to develop exosome-mimetic structures.
The main functional components of exosomes to be
incorporated in mimetic materials have been reviewed
[13]. The three main components of exosomes
reported were lipids, membrane proteins and therapeu-
tic cargo.
One of the main advantages of fully artificial EVs
over previous strategies is the production of pure and
well-defined biomaterial. In addition, production stra-
tegies of artificial EVs based on liposomes are more
sustainble and easier to scale up [11,89]. This fact is
quite important for preclinical and clinical studies and
in order to manufacture products ready to be sent to
the market [2].
Liposome preparation techniques have been exten-
sively reviewed [89–101], but not all the methods yield
vesicles suitable for becoming an artificial exosome. It
could be considered that only small unilamellar vesicles
(SUVs) are ideal precursors due to their similarities to
natural exosomes (size range and membrane
disposition).
Methodologies for SUV preparation (Table 5) can
be classified according to different criteria [92]. For
example, number of steps to reach SUV. Another
classification is based on the physical principle
applied to prepare vesicles: mechanical processes,
organic solvent replacement, detergent removal and
other techniques as microfluidic-based methods.
Reverse-phase evaporation, ethanol injection method,
ether injection method (EtIM), thin-film hydration
method (TFH), homogenization techniques, French
press cell extrusion, microfluidization, extrusion over
membranes, ultrasound and membrane contactors are
some of the techniques developed for SUV
preparation.
All these techniques rely on the self-assembly of
amphiphilic molecules, such as lipids, in ordered struc-
tures due to their physicochemical behaviour in aqu-
eous media [93,94]. This principle is the basis of
bottom-up nanotechnology. Vesicles with a size range
similar to that of natural EVs could be obtained [95]
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when operational variables were oprtimized by design
of experiments. In addition, a wide spectrum of mole-
cules with biological activity, independently of their
physicochemical nature (hydrophilic or hydrophobic,
low molecular weight or macromolecules), can be
incorporated into liposomes, during or after their for-
mation [96].
Functionalization of liposomes with biomolecules is
possible, owing to the different headgroup-modified
lipids that are available [97]. Headgroup modification
usually includes a molecule of polyethylene glycol as a
spacer between the functional group and the polar
region of the lipid. This avoids the sterical hindrance
caused by the proximity of biomolecules and liposome
surface. The chemical modification includes the intro-
duction of different types of functional groups, such as
biotin, amine, maleimide, carboxylic acid, folate, cya-
nur, DBCO, azide and succinyl groups. These groups
determine the crosslinking strategy [98–101] which
should not compromise the biological function.
Bioconjugation should ideally be carried out under
mild conditions, aqueous media and chemoselectivity,
and with a high yield.
Successful conjugation of peptides/proteins with
liposomes can be checked using conventional molecu-
lar biology techniques such as dot-blot [15], SDS-
PAGE [102] or even flow cytometry [102]. A prelimin-
ary purification step is required in order to remove
unconjugated biomolecules. For this purpose, the
authors have used classical separation methods, such
as ultracentrifugation [102] or gel filtration [15,103]
(SEC) with high exclusion limit resins (Sepharose CL-
2B, 4B mainly). Dialysis, however, is not used due to
the high molecular weight of biomolecules selected for
mimicking exosomes.
Undecorated liposomes have also been used in the
EV research field as EV models for comparing isolation
efficacy and physical integrity [47], detection by flow
cytometry [104] and EV refractive index study [105].
However, their use as a scaffold for artificial EV devel-
opment could offer new possibilities in basic research
about EVs and theranostic applications. To date, there
have been few examples of this approximation for the
development of mimetic exosomes, and no compara-
tive results are available owing to the great differences
between the methods used. A summary of the main
experimental work on mimicking exosomes by bottom-
up nanotechnology is given in Table 6 and briefly
commented on below.
The most frequent preparation technique for SUVs
as templates for EVs mimicking is the TFH method
combined with extrusion over polycarbonate mem-
branes and with [102] or without [15] previous
freeze–thaw cycles. Martínez-Lostao et al. [102] had a
formulation that included lipids and stoichiometry
inspired in natural exosomes. The introduction of
only 5% (w/w) of an iminodiacetic acid derivative or
DOGS-NTA allowed the binding of APO2L/TRAIL-
Table 5. Advantages and disadvantage of most frequently used methods for small unilamellar vesicles (SUVs) preparation.
Method
One-step method for
SUVs preparation
Physical method
applied for preparation Advantages Disadvantages
Ether injection
method
Yes Organic solvent
replacement
Scale-up adapted
High hydrophobic compound
encapsulation
No mechanical degradation of
compounds
Not suitable for thermosensitive
compounds
Solvent not suitable for some
biocompounds
Ethanol
injection
method
Yes Organic solvent
replacement
Scale-up adapted
Non-dangerous substances are handled
High hydrophobic compound
encapsulation
No mechanical degradation of
compounds
Ultrasounds are needed when
concentrated samples are produced
Low encapsulation efficacies of low-
molecular-weight hydrophilic
compounds
Not suitable for thermosensitive
compounds
Reverse-phase
evaporation
No Emulsification/organic
solvent replacement
Widely used
Suitable for mass production
Frequently used solvents are not suitable
for some biocompounds
Thin-film
hydration
method
No Mechanical processes Applied for any type of amphiphilic
molecules
High encapsulation of Hydrophilic
compounds compared to other
methods
Difficult to scale up production
Timely and cost-ineffective due to
necessary downsizing techniques
Downsizing
Techniques
French press cell
extrusion
Microfluidization
Extrusion over
membranes
/ Mechanical processes Good reproducibility
Adapted to scale-up requirements
Product loss associated with clogging of
membrane by concentrated samples
Ultrasounds Yes Mechanical processes Simple methodology
Possibility of being scaled up
Degradation of biological compounds
Scale-up unadapted
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His10 to liposomes in a single step. Its bioactivity was a
higher activity than that of the soluble ligand.
Moreover, a treatment based on these synthetic exo-
somes achieved 60% of disease improvement in a rheu-
matoid arthritis-induced animal model. In another
study, liposome-bound Apo2L/TRAIL overcame the
resistance to the soluble ligand exhibited by chemorre-
sistive tumour cell mutants [106]. The mechanism of
action of LUV-TRAIL in haematologic cells [107] was
also studied using mimetic structures of exosomes.
Another approximation to artificial EVs (exosomes)
for therapeutic purposes was carried out by De la Peña
et al. [15] using a reported formulation [108,109]. The
main components were phosphatidylcholine and cho-
lesterol, and headgroup-modified lipids such as DSPE-
PEG DSPE-PEG-MAL. In order to make traceable
NVs, both in vivo and in vitro, a fluorescent lipid was
included in the formulation, and magnetic nanoparti-
cles (SPIONs) were encapsulated during a thin-film
hydration step. After optimization of chemical-acti-
vated ligands binding, mimetic SNVs simulating DCs
derived exosomes were successfully tested as new tools
in basic and clinical immunology. A T-cell expansion
rate higher than that with previously reported experi-
ments using conventional methods was achieved.
An innovative methodology for the production of
protein encapsulated nanoliposomes was also reported
[103]. This produced 82 ± 4 nm antibody-coated lipo-
somes with approximately 93% EE of BSA. The pre-
paration route that combined a micro-emulsion
contained the protein to be encapsulated, with micelles,
in order to create a lipid bilayer formed through layer-
by-layer assembly. In this work, the authors selected a
Box–Behnken experimental design to optimize (max-
imize) the EE by adjusting some formulation para-
meters. The final optimized formulation is
summarized in Table 6. In this particular case,
researchers selected mimetic exosomes for the potential
transmission of antigen to DCs by a controlled target
delivery using a conjugated monoclonal antibody anti-
DEC205, a highly expressed receptor on the surface of
DCs. The introduction of cholesterol succinate in the
outer layer of the liposomes allowed the bioconjugation
of the Ab by EDC/NHS chemistry.
Despite the promising results and the advantages of
these methods for the development of liposome-based
artificial EVs, there are several limiting aspects that
hinder the transfer to the clinical field. While techno-
logical progress has allowed the design, development
and production of nanomedicines with high pharma-
ceutical grade, their clinical impact has been smaller
than expected due to a lack of sufficient information
about in vivo interactions and fates inside the human
body [11]. Specific challenges [13] are related to the
functionalization of vesicle surface with a combina-
tion of functional proteins at the same time because
actual methodologies are time-consuming and
because of the incorporation of nucleic acids with
acceptable efficiencies. The dependence of vesicle for-
mulation on parameters such as fusion properties and
stability could be another limit of special relevance to
immunotolerance. Finally, the knowledge about key
components in exosomes is not yet complete, since
they may vary from one cell line to another. They
could even be health-state-dependent and sensitive
to harvesting conditions.
Table 6. Summary of published work about the development of mimetic EVs nanovesicles by bottom-up bio-nanotechnology,
showing formulation of the vesicles, molecules for the surface functionalization and main physical characteristic (size).
Formulation Preparation method Conjugation strategy Size Protein for functionalization Reference
PC:SM:Cho:DOGS-NTA
(55:30:10:5) weight ratio
For fluorescent labelling, 0.25%
mole/mole DSPE-RhodB
Thin-film hydration
method (KCl 100 mM,
HEPES 10 mM pH 7.0,
EDTA 0.1 mM; KHE
buffer)
Filtered and degassed +
extrusion over 200 nm
membranes
Ni2+-NTA headgroup
functionalized lipid +
histidine-tagged
recombinant
peptides
37°C, 30 min
150–200 nm APO2L/TRAIL-His10 [102]
PC:Cho:DSPE-PEG:DSPE-PEG-MAL
(1:0.5:0.04:0.01) Molar ratio
For fluorescent labelling, 1% of
PC amount of DSPE-RhodB
Thin-film hydration
method (Hepes 25mM,
NaCl 140mM; pH 7.4)
Filtered and degassed +
extrusion over 100 nm
membranes
Maleimide headgroup
functionalized lipid +
Traut’s reagent protein
activation
1h RT 20/1 ratio
100 nm MHC class I peptide complexes and
FAB regions against T-cell
receptors (adhesion, early and
late activation and survival)
[15]
Micro-emulsion phase
PC:CpEL
(7:3, w/w)
Micelle phase
In 10:1 v/v DE:A
DOPE:DC-Cho
(4:1, w/w)
In 1:2 v/v EtOH:DW
Micro-emulsion and
micelle combining
method + sonication
step for 3min
Carboxilic group from
ChoS and amine
group from protein
EDC/NHS
4°C for 12 h
82 nm Monoclonal antibody against
DEC205 antigen expressed on
dendritic cells
[103]
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Despite attempts to mimic the exosome natural lipid
composition, there is a need for actually checking
whether the formulation is active and involved in the
expected functions or is just a passive element involved
only in the scaffolding of true functional elements.
Comparison of the efficiency of the intended integrated
component in differently formulated vesicles could be
an interesting experiment to elucidate the role of mem-
brane components. Parameters of uptake route and
incorporation efficiency could also be measured with
different cell lines, in order to assess the role of the
target cell. Other compounds as an alternative to lipids,
with a high grade of biocompatibility, could also be
used for the formulation of artificial exosome bilayers.
One option is to use non-ionic surfactants [110] for the
preparation of niosome-based artificial exosomes.
These compounds offer several advantages [111] over
lipids, such as price, versatility and sustainability. On
the other hand, their chemical structure offers
enhanced stability from both a chemical and physical
point of view. Niosomes with a size range close to that
of EVs can also be produced [95].
In recent years, microfluidics has been playing an
important role in the development of enhanced vesi-
cular systems, enabling robust and highly controlled
preparation routes of vesicles [112] and allowing
rapid characterization of products [113]. Another
important aspect in the development of exosome-
based therapy, regarding any preparation route, is the
creation of reduced systems for the study of traffic and
delivery into in vivo microenvironments [19]. Again,
microfluidic-based systems are opening up new possi-
bilities by the development of organ-on-a-chip plat-
forms that enable the study of these processes in an
innovative and highly efficient way [114].
It is expected that microfluidic synthesis of nanove-
sicles will open the path for new artificial EV routes,
with the required control of size and EE, and minimal
consumption of reagents.
Other recently explored drug-delivery systems have
developed platelet-mimetic nanoparticles by also using
bottom-up technology. These authors have produced
unilamellar polymeric nanoparticles functionalized
with immunomodulatory and adhesion antigens, and
they have tested them as another approach to disease-
targeted delivery [115].
Conclusions and future perspectives
Knowledge about all the biological aspects related with
EVs, especially exosomes, has opened up new frontiers in
the clinical field. After an explosion of publications in
recent years about the role of EVs in physiological and
pathological conditions, novel opportunities for the
development of enhanced therapeutic biomaterials have
arisen. These observations could help in the production
of new materials inspired by natural vesicles, without the
classical inconveniences associated with up-to-date syn-
thetic alternatives (liposomes, polymersomes, inorganic
nanoparticles, etc.). EV-based therapies include tissue
regeneration or immunomodulation, but drug delivery
is one of the most promising applications. Production,
isolation, modification and purification at a large-scale
clinical grade are the main limitations of EVs becoming a
true clinically settled therapeutic agent.
These limitations have promoted the development
of mimetic materials inspired by EVs, the so-called
artificial EVs. In this article, we have introduced a
systematic classification of the types of artificial EVs
according to their preparation routes. Two well-defined
strategies have been developed: semi-synthetic or fully
synthetic products. The first strategy uses natural exo-
somes as precursors that are modified at the moment
of their biogenesis (pre-isolation modifications),
whereas the second strategy modifies the vesicles after
their release by cells and their isolation from cultured
media or biological fluids. Genetic engineering-based
modifications, active loading platforms, specific signal-
ling sequences for selective sorting or precursor cell
modifications with nanomaterials are some of the
methods developed for exosome-based semi-synthetic
nanovesicle production.
Fully synthetic vesicles with EVs mimetic properties
can be produced by bio-nanotechnology. Top-down
techniques that produce vesicles made of membrane
fragments obtained from the extrusion or slicing of
cells, or bottom-up techniques that take advantage of
supra-molecular chemistry (mainly self-assembly) to
produce vesicles from individual molecules, represent
the technology developed for that purpose.
Despite the great potential of artificial EVs, some
limitations to their development as therapeutic tools
have been identified. There is no perfect technique,
and, depending on the final purpose of artificial EVs,
combinations of procedures could offer new insights in
the field. Systematic studies with different cellular ori-
gins and target cell lines would expand and consolidate
the applications of artificial exosomes. Comparative
work including the encapsulation into different artifi-
cial vesicles would be interesting in order to identify
effects due to the carrier.
Multidisciplinary teams with complementary actions
in the fields of applied biology, pharmacology, chemi-
cal engineering, material sciences and medicine would
allow the definitive consolidation of these therapeutic
biomaterials in clinical routines.
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Highlights
● A new systematic classification of artificial EVs is
provided.
● Bio-engineering modification of naturally released
exosomes is summarized.
● Relevant examples in pre- or post-released mod-
ifications are presented.
● Bio-nanotechnological methods for fully artificial
EVs generation are compelled.
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